# Non-Dihydropyridines

## Examples

- `verapamil` (phenylalkylamine group)
- `diltiazem` (benzothiazepine group)

> These act mainly on the heart — reducing heart rate, contractility, and conduction — with moderate vasodilation.

## Mechanism of Action (MOA)

- Block **L-type voltage-gated Ca²⁺ channels** in **cardiac muscle**, **SA node**, **AV node**, and **vascular smooth muscle**.
- ↓ **Ca²⁺ entry** → ↓ contractility (negative inotropy) and **slowed conduction** (negative chronotropy/dromotropy).
- `Verapamil`: strongest cardiac depressant, weakest vasodilator.
- `Diltiazem`: intermediate action on both heart and vessels.

## Pharmacodynamics

- **Heart:**
  - ↓ SA node firing → ↓ heart rate
  - ↓ AV node conduction → slows ventricular response (useful in SVT, AF)
  - ↓ myocardial contractility → ↓ O₂ demand

- **Vessels:** Moderate vasodilation → ↓ afterload, ↓ BP
- **Overall:** Antihypertensive, antianginal, and antiarrhythmic actions.

## Pharmacokinetics

| Drug        | Route    | Onset        | Duration | Remarks                                                              |
| ----------- | -------- | ------------ | -------- | -------------------------------------------------------------------- |
| `verapamil` | Oral, IV | 1–2 h (oral) | 6–8 h    | Extensive first-pass metabolism; mainly hepatic (CYP3A4)             |
| `diltiazem` | Oral, IV | 30–60 min    | 6–9 h    | Intermediate onset; hepatic metabolism; some sustained-release forms |

## Indications

- **Hypertension** (especially with angina or arrhythmia)
- **Angina pectoris** (chronic stable and variant/Prinzmetal)
- **Supraventricular arrhythmias** (SVT, AF, atrial flutter – especially `verapamil`)
- **Hypertrophic cardiomyopathy** (rate control, ↓ outflow obstruction)

## Adverse Effects

- **Bradycardia**, **AV block**, **heart failure exacerbation**
- **Constipation** (notably `verapamil`)
- **Hypotension**, dizziness
- Facial flushing, headache
- **Edema** (less than dihydropyridines)
- Nausea, fatigue

## Cautions

- Avoid combining with **β-blockers** → risk of severe bradycardia or AV block.
- Use cautiously in **heart failure**, **hypotension**, or **elderly** patients.
- Monitor ECG when used IV or with other rate-slowing drugs (e.g. `digoxin`, `amiodarone`).
- Dose adjustment in **hepatic impairment**.

## Contraindications

- **Severe bradycardia** or **AV block (2nd/3rd degree)**
- **Heart failure (reduced EF)**
- **Hypotension**
- **Sick sinus syndrome** (without pacemaker)

## Key Points Summary

| Feature                            | Description                                             |
| :--------------------------------- | :------------------------------------------------------ |
| **Site of action**                 | Mainly **heart** (SA, AV node, myocardium)              |
| **Effect on heart rate**           | ↓ (negative chronotropy)                                |
| **Effect on contractility**        | ↓ (negative inotropy)                                   |
| **Effect on conduction (AV node)** | ↓ (negative dromotropy)                                 |
| **Main antihypertensive effect**   | ↓ Cardiac output + moderate vasodilation                |
| **Best used in**                   | Hypertension with angina or supraventricular arrhythmia |
| **Strongest cardiac effect**       | `verapamil`                                             |
| **Balanced cardiac + vascular**    | `diltiazem`                                             |
| **Main side effects**              | Bradycardia, constipation (`verapamil`), AV block       |
| **Avoid combination with**         | β-blockers, digoxin                                     |
| **Avoid in**                       | Heart failure, severe bradycardia, hypotension          |
